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886Late graft explants in endovascular aneurysm repair
Eric J. Turney, MD, Sean P. Steenberge, MS, Sean P. Lyden, MD, Matthew J. Eagleton, MD,
Sunita D. Srivastava, MD, Timur P. Sarac, MD, Rebecca L. Kelso, MD, and Daniel G. Clair, MD,
Cleveland, Ohio
Objective:With more than a decade of use of endovascular aneurysm repair (EVAR), we expect to see a rise in the number
of failing endografts. We review a single-center experience with EVAR explants to identify patterns of presentation and
understand operative outcomes that may alter clinical management.
Methods: A retrospective analysis of EVARs requiring late explants, >1 month after implant, was performed. Patient
demographics, type of graft, duration of implant, reason for removal, operative technique, length of stay, complications,
and in-hospital and late mortality were reviewed.
Results: During 1999 to 2012, 100 patients (91% men) required EVAR explant, of which 61 were placed at another
institution. The average age was 75 years (range, 50-93 years). The median length of time since implantation was
41 months (range, 1-144 months). Explanted grafts included 25 AneuRx (Medtronic, Minneapolis, Minn), 25 Excluder
(W. L. Gore & Associates, Flagstaff, Ariz), 17 Zenith (Cook Medical, Bloomington, Ind), 15 Talent (Medtronic), 10
Ancure (Guidant, Indianapolis, Ind), 4 Powerlink (Endologix, Irvine, Calif), 1 Endurant (Medtronic), 1 Quantum LP
(Cordis, Miami Lakes, Fla), 1 Aorta Uni Iliac Rupture Graft (Cook Medical, Bloomington, Ind), and 1 homemade tube
graft. Overall 30-day mortality was 17%, with an elective case mortality of 9.9%, nonelective case mortality of 37%, and
56% mortality for ruptures. Endoleak was the most common indication for explant, with one or more endoleaks present in
82% (type I, 40%; II, 30%; III, 22%; endotension, 6%; multiple, 16%). Other reasons for explant included infection (13%),
acute thrombosis (4%), and claudication (1%). In the ﬁrst 12 months, 23 patients required explants, with type I endoleak
(48%) and infection (35%) the most frequent indication. Conversely, 22 patients required explants after 5 years, with type
I (36%) and type III (32%) endoleak responsible for most indications.
Conclusions: The rate of EVAR late explants has increased during the past decade at our institution. Survival is higher
when the explant is done electively compared with emergent repair. Difﬁculty in obtaining a seal at the initial EVAR often
leads to failure#1 year, whereas progression of aneurysmal disease is the primary reason for failure >5 years. (J Vasc Surg
2014;59:886-93.)Endovascular aneurysm repair (EVAR) has increased in
use during the past decade and now has become the
primary mode of treatment of infrarenal abdominal aortic
aneurysms (AAAs) in private and academic practices.1 In
addition, clinicians have continued to push the limits of
the application of the technology, attempting to address
more challenging anatomic conditions outside the instruc-
tions for use (IFU).2,3 The long-term success of EVAR
requires surveillance imaging to identify problems that
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number of patients treated, the number presenting without
further options for endovascular salvage will likely produce
an increasing population needing open conversion.
A large review has found that the overall incidence of
late conversion is 1.9% (range, 0.4%-22%)4 and that
delayed rupture risk is 1% per year.5 EVAR can fail for
many reasons, including graft infection, rupture, migration,
component separation, thrombosis, device fracture or
failure, and aneurysm growth with or without endoleak.
Other authors have documented the frequency of endovas-
cular option use before open conversion.6,7 We reviewed
our institution’s growing experience for late conversion
of failed EVAR to better understand current results, predic-
tors of outcome, and reasons for failure.
METHODS
Patients were identiﬁed according to the Current
Procedural Terminology codes (American Medical Associ-
ation, Chicago, Ill) for open AAA repair, and International
Classiﬁcation of Diseases, 9th revision coding for AAA
at the Cleveland Clinic Foundation between January 1,
1999, and December 31, 2012. We reviewed all operative
reports to identify EVAR explants. After Institutional
Review Board approval, a Research Electronic Data
Capture database was generated. Patients were only
included if the endograft was removed >30 days after
implantation. We also included patients who underwent
Table I. Graft type
Graft type No.
AneuRxa 25
Excluderb 25
Zenithc 16
Talenta 15
Ancured 10
Powerlinke 4
Enduranta 1
Quantum LPf 1
Aorta Uni Iliac Rupture Graftg 2
Homemade 1
aMedtronic, Minneapolis, Minn.
bW. L. Gore & Associates, Flagstaff, Ariz.
cCook Medical, Bloomington, Ind.
dGuidant, Indianapolis, Ind.
eEndologix, Irvine, Calif.
fCordis, Miami Lakes, Fla.
gCook Medical, Bloomington, Ind.
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surgical attempts to repair endoleaks or increase graft ﬁxa-
tion without graft were excluded.
Patient demographics, EVAR type, operative factors,
and complications were recorded. Demographic informa-
tion included sex, duration of implant, age, and comorbid-
ities such as coronary artery disease, chronic obstructive
pulmonary disease, and chronic renal failure (glomerular
ﬁltration rate <60 mL/min/1.73 m2). Graft information
included reason for explant, partial or full excision, facility
where implanted, and need for elective, urgent, or emer-
gent explant. Reasons for explant included endoleak by
type, infection, migration, aneurysm enlargement, and
rupture. Society for Vascular Surgery reporting standards
were used to deﬁne migration, aneurysm enlargement,
and endoleak type. Operative factors included repair type,
surgical approach, clamp position, duration of clamp, and
creatinine levels preoperatively and postoperatively and
the peak level during the hospital stay.
We identiﬁed patients from our previous analysis in
20098 and compared outcomes for patients who under-
went repair after that point. We compared modes of failure
for conversions #1 year, between 1 and 5 years, and
>5 years.
Outcomes analyzed were 30-day mortality, arrhythmia,
myocardial infarction, pneumonia, prolonged ventilation,
temporary hemodialysis, permanent hemodialysis, length of
stay, and long-term survival status. Statistical analysis was per-
formed using R software (The R Foundation for Statistical
Computing, http://www.r-project.org/foundation/) and
Excel (Microsoft Corp, Redmond, Wash). Analysis of associ-
ations with 30-day mortality was performed using Pearson c2
tests and Fisher exact tests for categoric factors andWilcoxon
rank sum tests for continuous measures. Kaplan-Meier esti-
mates and Cox proportional hazard models were used to
compare long-term survival. Owing to the small number
of 30-day and long-term mortality events, multivariable
modeling was not performed for either outcome. Statistical
signiﬁcance was identiﬁed for a P value <.05.
RESULTS
From 1999 to 2012, our institution performed 1881
EVARs and 2075 open infrarenal aortic repairs. During
this interval, 100 patients required late graft explant, of
which 61 were placed at another institution. Six acute graft
explants were excluded from analysis. Multiple types of
EVAR devices have been explanted (Table I). We have
noted an increased frequency of EVAR explant, performing
28 in the last 2 years (Fig 1). Suprarenal ﬁxation was
present in 37% of stent grafts removed.
Cohort characteristics. Patients were an average age
of 75 years (range, 50-93 years) and 91 were male. Coro-
nary artery disease was present in 66%, chronic obstructive
pulmonary disease in 23%, and chronic kidney disease in
24%, with two or more present in 28%. The average preop-
erative serum creatinine was 1.3 mg/dL (range, 0.5-
4.68 mg/dL). We did not ﬁnd a difference in patient
demographics compared with the patient populationreported in 2009. The only difference we identiﬁed in
the EVARs explanted since our original report is that we
have converted a higher proportion of patients whose orig-
inal EVAR was done at another institution, 15 patients
(38%) and 46 patients (77%), respectively (P < .001).
Grafts were excised after a median of 41 months
(range, 1-144 months), with 71 explants performed elec-
tively. Overall, endoleak was present in 82% of patients,
some with multiple types. Type I endoleak was the most
frequently occurring, present in 40% of total patients, fol-
lowed by type II in 30%, and type III in 22%. Finally, endo-
tension was present in 6%. Also contributing to the
indications for explantation were graft migration in 15
patients and claudication in one. The claudication patient
who required explant was before 2009 and is detailed in
our prior report.8
Limb thrombosis in six patients contributed to the
indication for explant. One had claudication and one had
bilateral limb thrombosis with acute limb ischemia, and
both were previously described.8 Two patients had prox-
imal migration causing limb occlusion leading to the choice
to explant. One had multiple limb occlusions treated
several times with thrombolysis before deciding to remove
the device. The last patient with limb thrombosis had prox-
imal migration and developed a symptomatic aneurysm.
Urgent or emergent repairs were done in 29 patients.
Ten patients were treated urgently with seven staged
reconstructions for infected stent grafts. Repairs were
emergent in 19 patients, including infection in 3, rupture
in 9, acute limb ischemia in 2, and a symptomatic nonrup-
tured aneurysm in 5. The ﬁve patients with symptomatic
aneurysm treated emergently had endoleaks contributing
to the problem, comprising type I in 2, type II in 2, type
III in 1, and type V in 1. One patient had only type II
endoleak and a symptomatic expanding aneurysm.
Two patients were originally treated at Cleveland
Clinic for ruptured aneurysm in a physician-sponsored
investigational device exemption trial with an aortouniiliac
Fig 1. Number of explants per year.
Fig 2. Time to explant.
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rent rupture.
Infected grafts were treated with several methods. One
patient was treated with excision and femoral vein recon-
struction, eight were treated with axillobifemoral bypass
and removal (one simultaneous), and four were treated
with excision and replacement with rifampin-soaked poly-
ester grafts.
Twenty-three patients required explant <12 months
after EVAR, with an additional 22 performed $5 years
after placement (Fig 2). The primary indication for graft
removal by time period is detailed in Table II.
Operative characteristics. The operative approach
was determined by surgeon preference and clinical factors
such as the presence of suprarenal ﬁxation, extent of prox-
imal and distal repair required, and the reason for failure.
Our overall operative approach has not changed since our
prior report. The approach was retroperitoneal in 56% of
patients and transabdominal in 44%. Supraceliac clamping
was required in 54 patients, suprarenal in 33, and infrarenalin 13, with an average clamp time of 35 minutes. Clamps
were generally placed above the entire endograft, with
few exceptions, when distal issues led to the failure and
proximal ﬁxation was not compromised. Aortobiiliac repair
was performed in 65 patients and was the most common
type of reconstruction required. This was followed by
tube graft in 18 patients, aortobifemora1 in 8, axillobife-
moral in 7, aortouniiliac in 1, and no repair in 1. Nine
patients required revascularization of visceral or renal
vessels. Stent grafts were partially excised in 22 patients,
with 17 of those leaving distal limb components and four
proximal components and one patient with both.
Average length of stay was 15 days (range, 1-56 days),
with in hospital complications including arrhythmia in 25
patients, myocardial infarction in 6, prolonged ventilator
support in 26, pneumonia in 7, and hemodialysis in 9, of
which one was temporary. Complications rates by time
cohort are detailed in Table III and did not change. Renal
failure requiring dialysis developed in six patients, all of
whom had a supraceliac clamp, with an average clamp
Table II. Indication for explants by duration (patients
may have more than one)
Reason for explant
1 year,
No. (%)
1-5 years,
No. (%)
$5 years,
No. (%)
Type I endoleak 11 (38) 19 (35) 8 (36)
Initial seal 7 5 1
Migration 3 4 1
Disease progression 1 10 6
Type II 1(3) 11 (20) 2 (9)
Type III 1(3) 13 (24) 7 (32)
Type V 0 4 (7) 2 (9)
Infection 8 (28) 4 (7) 1 (5)
Occlusion 3 (3) 1 (2) 2 (9)
Claudication 3 (10) 0 0
Unknown 0 1 (2)a 0
Mortality 4 (14) 11 (20) 2 (9)
aPatient presented with free rupture, and the reason for rupture was not
identiﬁed.
Table III. Outcomes
Variable Total
Initial cohort,
No. (%)
New cohort,
No. (%) P
30-day mortality 17 9 (23) 8 (13) .36
Complication
Cardiac 29 13 (33) 16 (27) .69
Pulmonary 26 10 (25) 16 (27) .99
Renal 9 5 (12.5) 4 (6.67) .48
Any 44 19 (47.5) 25 (41.67) .71
Table IV. Mortality rates by indication
Variable Total, No. Mortality, No. (%)
Elective 71 7 (9.90)
Nonelective 29 10 (34)
Emergent 19 7 (37)
Infected grafta 13 5 (38)
Aortoenteric ﬁstulaa 5 3 (60)
Rupture 9 5 (56)
aSome of the infected grafts and patients with aortoenteric ﬁstula were done
urgently with a staged reconstruction, whereas others were unstable and
done emergently at single setting.
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35 minutes. Overall 30-day mortality was 17%, with 9.9%
mortality in elective cases and 34% in nonelective cases.
Mortality rate by indication is described in Table IV.
Univariate predictors of 30-day mortality. The 30-
day mortality was predicted by multiple factors that
reached statistical signiﬁcance. Renal or visceral revascu-
larization was required in nine of the 100 patients, with
a 30-day mortality of 44% (P ¼ .036). Conversely, the
mortality rate was 13% in those who did not require renal
or visceral revascularization. The second factor to reach
statistical signiﬁcance was clamp position in the supra-
visceral position, which was required in 54 patients, with
a mortality rate of 24% (P ¼ .001). Suprarenal clamping
was required in 33 patients, with no deaths, and infrarenal
clamping was performed in 13 patients, but the associated
30% mortality was not statistically signiﬁcant. The pres-
ence of infection, which occurred in 13 patients, also
reached statistical signiﬁcance with respect to mortality at
38% (P ¼ .038). The 19 patients who were repaired
emergently and the nine who presented with rupture had
a statistically signiﬁcant worse 30-day mortality of 37%
(P ¼ .015) and 55% (P ¼ .006), respectively (Table V).
The 71 patients who underwent elective procedures had
a statistically signiﬁcant lower 30-day mortality at 9.9%
(P ¼ .006).
Finally, the 30-day mortality can be predicted by peak
creatinine and postoperative creatinine levels, which were
statistically signiﬁcantly elevated (2.5 mg/dL; P < .001;
1.9, mg/dL; P < .001) compared with those who did
not die #30 days (1.4 and 1.06 mg/dL, respectively). A
number of factors did not predict 30-day mortality,
including age, sex, presence of coronary artery disease,
chronic obstructive pulmonary disease, chronic renal
failure, presence of suprarenal ﬁxation, operative approach,
clamp time, partial excision, and aneurysm enlargement.
Type II endoleaks were associated with statistically signiﬁ-
cant improvement in 30-day mortality, present in 30% of
explanted patients and a mortality of 3% (P ¼ .025).Univariate predictors of long-term survival. Overall
survival after open conversion was evaluated with a Cox
proportional hazard model and with Kaplan-Meier esti-
mates. This analysis demonstrated that the presence of
chronic obstructive pulmonary disease, visceral revascular-
ization, infection, emergent repair, rupture, and elevated
creatinine conveyed an increased risk for death. Conversely
an elective repair, presence of type II endoleak, and
aneurysm enlargement predicted a decrease risk of death
(Table VI).
A comparison with patients from our previous series in
2009 found no statistically signiﬁcant difference in demo-
graphics, procedural details, or outcomes. The indications
for explant in the initial cohort included type I endoleaks
in 16 (40%), type II in 8 (20%), type III in 11 (28%),
and infection in 4 (10%). Indications in the new cohort
were type I endoleak in 24 (40%), type II in 22 (37%),
type III in 11 (18%), and infection in 9 (15%). There
was no statistically signiﬁcant difference in these factors
as well.
DISCUSSION
The need for open conversion of failing endografts has
accelerated during the last several years at our institution.
This is most likely due to the growing number of patients
having had EVAR, because this is the most common way
AAAs are treated in the United States. The initial repair
in most of our patients (n ¼ 61) was done at another
facility, and many of the patients underwent attempted
endovascular salvage before open conversion. The details
of those interventions before referral for conversion were
unavailable for this analysis. Pre-EVAR implant imaging
was not available for most patients, making it difﬁcult to
Table V. Predictors of 30-day mortality
Variable
Survival
P
With variable
(n ¼ 17)
Without variable
(n ¼ 83)
Median age (range), years 77 (55-85) 75 (50-93) .58
Male sex 78 5 .67
Coronary artery disease 54 29 .99
COPD 19 64 .99
Chronic renal failure 20 63 .99
Suprarenal ﬁxation 32 51 .67
Visceral revascularization 2 81 .036
Supraceliac clamp 41 42 .001
Emergent 12 71 .015
Infection 8 75 .038
Rupture 4 79 .006
COPD, Chronic obstructive pulmonary disease.
Table VI. Factors predictive of overall survival
Predictor HR P
Negative predictors
COPD 2.19 .038
Visceral revascularization 4.02 .003
Infection 3.27 .002
Emergent 4.07 <.001
Rupture 5.44 <.001
Creatinine
Preoperative 2.1 .004
Postoperative 2.02 <.001
Peak 1.37 <.001
Positive predictors
Type II endoleak 0.36 .035
Elective operation 0.2 <.001
Aneurysm enlargement 0.37 .005
COPD, Chronic obstructive pulmonary disease; HR, hazard ratio.
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difﬁculty assessing angulation, neck diameters, and neck
features after implant, but the effect of the device on these
measurements may lead to potential errors in assumption
of the reason for failure.
Conversion was elective in most patients in our series,
with endoleak and aneurysm enlargement as the primary
indication. Compared with our previous series, the rate of
device migration was lower, perhaps a reﬂection of
improved device technology. Some data suggest that aneu-
rysm growth of >8 mm, or absolute size >7 cm, deﬁnes an
increased risk for rupture, although rupture can still occur
in stable or shrinking aneurysms.9
It is accepted type I and III endoleaks should be
aggressively treated, but the threshold for explantation
with type II or no endoleaks visualized remains to be estab-
lished.4,10-12 We have used >5 mm growth without an
identiﬁable and treatable cause as indication for explant.
We found varied indications for conversion relative to
the time period they presented after EVAR. The most
common indication in patients presenting #1 year of
EVAR for explant was type Ia endoleak or graft infection.
The type Ia endoleaks in these patients were typically in
disadvantaged necks that were short, angulated, or conical
and typically outside of most device IFU. The willingness
to push the envelope with endograft placement in chal-
lenging anatomy and less than ideal adherence to the
device IFU, as touted by many authors, may also play an
important role in earlier failures.2,13-15 The increased use
of EVAR for ruptured aneurysms, when durability of repair
is often a secondary consideration, has also been a factor
contributing to an increased need for late conversion in
other series.16,17 We have seen a reduction of conversions
in our own patients. Although we are not sure of the
reason, we have limited our use of commercial devices
outside of the IFU. This approach has been inﬂuenced
by the increased referral for EVAR failure and the avail-
ability of branch and fenestrated devices to treat this
anatomy in a physician-sponsored investigational device
exemption trial at our institution. This contrasts with otherrecent series where most conversions were implanted at the
same institution.7
Patients who required explant>5 years most commonly
presented with type Ia or type III endoleaks. The type Ia
endoleaks were typically from aneurysmal degeneration of
the proximal sealing zone, and the type III endoleaks
were typically from material failure. The average time to
open conversion is variable across case series, but compared
with our previous experience, there has been an overall
increase, with six patients being more than a decade since
EVAR. The increased type III endoleaks in the devices pre-
senting for conversion >5 years as well as the failure of
a patient >10 years after the initial implant underscores
the fact that surveillance should not have an end point.
Most patients in our series who required explant had an
endoleak, with type II endoleaks present in 30%. A type II
endoleak was never the cause of aneurysm rupture in
a patient in our series, although this phenomenon has
been reported.18 In one patient with a symptomatic
enlarging aneurysm, we only found a type II endoleak.
We and others have previously noted that the continuous
pursuit of endoleaks with multiple secondary interventions
reaches a point of futility where deﬁnitive open repair
becomes prudent.8,19,20 We only recommend treatment
of type II endoleaks with conversion when endovascular
methods of treatment fail and aneurysm sac enlargement
continues.19 In several patients in our series, type II endo-
leaks were present with type I and III endoleaks, which
were the primary indication for conversion.
Emergent repair was most frequently required for
patients with infection or rupture. Morbidity and mortality
rates were similar to several recent studies, and our data
echo the signiﬁcantly better outcomes when performed
electively.21 Nonelective repair resulted in an overall
mortality of 37%, and 55% speciﬁcally for rupture.7,11 Graft
ﬁxation can have a direct effect on clamp position and time
as well as the potential need for aortic endarterectomy. We
frequently choose to clamp above the entire device. A supra-
celiac clamp position had a negative effect on outcomes,
likely due to the effect of visceral and renal ischemia. We,
JOURNAL OF VASCULAR SURGERY
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on outcome, suggesting that this can be done safely in most
patients even though suprarenal ﬁxation devices are
commonly covered with neointima and this is disrupted
and removed by aortic endarterectomy in many instances.
We would like to emphasize that well-incorporated
suprarenal stents may be difﬁcult to remove, and consider-
ation should be to leave those in place. Several new devices
are designed with more substantial active suprarenal ﬁxa-
tion, among them the Endurant (Medtronic, Santa Rosa,
Calif) and Ovation Prime (Trivascular, Santa Rosa, Calif),
compared with prior devices. These new-generation
devices may lead to worse outcomes during conversion if
longer clamp times are needed or damage occurs to the
visceral segment. The clamping of devices is possible, and
partial removal may be an important way to reduce compli-
cations and mortality when removing endografts.8,22 We
only left the proximal portion of the device in ﬁve patients
and have only done so when well incorporated and clearly
not associated with the failure mode of the device.
We found no signiﬁcant outcome differences in our data
in this report compared with our initial report of 41 patients
in 2009.8 Although not signiﬁcant, we did note a higher
mortality in elective cases in the current series (3.3% vs
9.9%). When patient and procedural details were evaluated,
no signiﬁcant difference between the two groups could be
found that might explain the reason for this ﬁnding.
Clearly, with increased experience in conversion, we
are more willing to offer this operation to patients without
alternatives. We have the ability to offer custom fenestrated
devices as a solution for failing EVAR devices; thus, not all
patients with failed EVAR have open conversion at our
institution. Some anatomic and device factors prevent
treatment with custom fenestrated devices. A few of our
patients without fenestrated or branch options who were
considered a prohibitive risk for open conversion were
not offered explant surgery. The disparity in outcomes after
emergent explantation, speciﬁcally for rupture, highlights
the importance of continued long-term surveillance as
well as when to proceed with open repair.
Multiple endoleaks are often encountered during graft
removal, with type I often the most common indication
and often implicated in rupture.16,21 Infectious etiologies,
with an incidence of 0.62%, represent a signiﬁcant popula-
tion of patients who require graft removal and often result
in poorer outcomes.23-25 Patients can present with a spec-
trum of pathology, from smoldering low-grade infection to
ﬂorid sepsis or exsanguination and, consequently, variable
urgency for graft removal. For patients who are unﬁt for
open repair, some series have suggested percutaneous
drainage and suppressive antibiotics as a short-term option,
but late failure has occurred.25-27 We successfully used
percutaneous drainage with antibiotic instillation as
a temporizing measure to control sepsis in one patient in
this series. This allowed the patient to be converted
without dying when better medically optimized.
The decision to remove all or part of the endograft
remains largely contested. Potential for delayedcomplications from the remnant endograft, such as migra-
tion and endoleak remains, particularly if all or a large frag-
ment of the graft remains. Owing to these risks, continued
surveillance imaging should be performed, which may not
be met with great patient compliance. However, well-
incorporated distal and proximal components can be difﬁ-
cult to remove, often leading to longer clamp times and
more signiﬁcant injury to the vessel wall. In addition,
surrounding venous structures can be damaged when there
is a large amount of inﬂammation. Some recent series have
suggested decreased morbidity and mortality when the
entire endograft is left intact, although bleeding complica-
tions were present postoperatively.22,28
The long-term risk for recurrence has not been estab-
lished, but one series noted freedom from secondary endo-
leaks at an average of 42 months of follow-up, whereas
another noted the need for further procedures after partial
removal.7,22 We still believe that optimally all graft material
should be removed if safe and technically feasible and
deﬁnitive repair is performed. When endograft explant is
performed for infection, all of the graft should be removed
to minimize persistent infection, and the best conﬁguration
of reconstruction remains undetermined.24,29 The follow-
up for patients with remnant endograft is a fusion of the
surveillance plan we use for endograft and open repairs,
with timing in part tailored to the patient.
CONCLUSIONS
The incidence of endograft failure continues to rise,
and the need for open conversion for salvage will grow
more prominent. Explant results are improved when per-
formed electively and are associated with mortality rates
that may exceed those found for elective primary repair.
Conversion for ruptured EVAR continues to have a very
high risk of death and complications. Type I and III endo-
leaks are most often associated with late rupture, and
surveillance is necessary to identify these issues early.
Endograft failure #1 year is most commonly due to failure
of the proximal seal at the initial procedure and under-
scores the need to understand device limitations when
used outside the IFU. Late failures are most commonly
due to aneurysmal degeneration of the seal zones and
device material failure and can occur even after a decade
of successful EVAR repair.
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understand what your algorithm is of treating patients with type I
or type II endoleaks? You talked about stent graft explants, but do
the patients initially undergo embolization procedures? Do you
use Palmaz stents and/or stent graft extensions prior to explants?
Dr Eric J. Turney. Some of the procedural algorithms are
very physician-dependent. But if it is felt that improvement in
seal would be obtained by a proximal extension cuff because there
is more landing zone, Palmaz stents have been utilized. If it is sus-
pected that it is in fact a type II endoleak and if they have not been
attempted to be addressed by endovascular means prior to referral,
then we do appropriately go down those courses.Dr William Quinones-Baldrich (Los Angeles, Calif). In
2007, Dr Jimenez from our center presented our initial experience
with conversions. We thought with more endovascular aneurysm
repairs (EVARs) being performed, we were going to see more
conversions but we haven’t. With availability of fenestrated grafts
at your institution, it is surprising that you are converting so
many of these patients. So my ﬁrst question is: Why were these
patients not candidates for a fenestrated repair or a proximal exten-
sion with a fenestrated graft?
You report that many of these patients required supraceliac
clamping. Very early in our experience, we recognized that we could
actually clamp the device with the aorta and just leave portions of it,
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imally. Distally, we could use the iliac limbsmost of the times, which
really simpliﬁes the conversion. In principle, you are ﬁxing the aneu-
rysm and don’t have to explant everything. My question is: How
often did you leave components of the endovascular repair to treat
the aneurysm without a complete explantation of the endografts?
DrTurney. I will address the second question ﬁrst.Most physi-
cians, again this is a preference, chose to clamp above the device. And
it has been, for themost part, our stance that removing the endograft
in its entirety is preferential unless it becomes technically not feasible
to remove. The number of patients total that had remnant proximal
anddistalwas 22%, I believe. But in patientswhohad infection, those
were always 100% excision every time.
The ﬁrst part of the question, the patients who weren’t from
a medical comorbidity deemed to be high risk were offered open
repair. There are patients who are being converted with fenestrated
options as well. And there were multiple factors that went into it, as
well as what the patient’s wishes were and whether or not the physi-
cian felt that open conversion was the appropriate step at that time.
Dr Thomas Forbes (London, Ontario, Canada). It is
certainly a large series that we can all learn a lot about. On one
slide you touched on some of the predictive factors from the orig-
inal operation. I wonder if you could expand on that a little bit
with respect to neck length and diameter and if there were any
differences between the type of graft that was used.
Dr Turney. We didn’t ﬁnd any differences with respect to the
type of graft used. In part, it is hard to tell because the denomi-
nator is something that is uncertain as far as the grafts that areout there. We have explanted every graft that is available on the
market, and it actually seems to mirror the number of the market
share that those devices have as far as how many we are explanting.
So it does not seem that either device has shown, from our data, to
be superior or inferior.
With regards to the neck anatomy, the patients with angulated
necks at the initial time of implantation, those who didn’t obtain
a good seal and had accessory efforts placed with Palmaz stents,
and those who had angulation and short necks were the ones
who had challenging neck anatomy from the initial time of
implantation.
Dr Cassius Chaar (New Haven, Conn). In the abstract you
mentioned that the mortality for elective conversion is 9.9%
compared with 3% in your prior series. I have looked at the
open conversions after EVAR at the University of Pittsburgh
Medical Center and I reviewed the literature. Most of the elective
conversions had a mortality of less than 5%. Why do you think
there was an increase in the mortality of elective open conversion
in the second group?
Dr Turney. Actually that was one of the things that initially
caught our eye when we were looking through the data, and we
expected that the comorbidity presence was going to be higher
in the patients who were in the newer group, but in fact, there
was no statistically signiﬁcant difference, and the difference in
mortality didn’t reach statistical signiﬁcance. We don’t know if it
is because we are being a little more willing to offer open conver-
sion to patients who are higher risk and it is just something that
hasn’t been borne out in the statistics yet.
